VBI VACCINES INC. (TSE:VBV) Files An 8-K Other EventsItem 8.01 Other Events.
On September 25, 2018, VBI Vaccines Inc. issued a press release announcing that the independent Data and Safety Monitoring Board completed its second safety assessment of the ongoing Phase 1/2a clinical study of VBI-1901 in recurrent glioblastoma. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
On September 26, 2018, VBI Vaccines Inc. issued a press release announcing formation of three scientific advisory boards. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
On September 27, 2018, VBI Vaccines Inc. issued a press release announcing that Jeff Baxter, President and CEO, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 1:30 p.m. ET at the Sofitel Hotel in New York City. A copy of the press release is attached as Exhibit 99.3 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
VBI Vaccines Inc/BC ExhibitEX-99.1 2 ex99-1.htm VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients – Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modification – Intermediate-dose study arm: enrollment complete – Initial immunologic data from low and intermediate-dose cohorts expected in the fourth quarter 2018 CAMBRIDGE,…To view the full exhibit click
About VBI VACCINES INC. (TSE:VBV)
VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).